Novo Nordisk announced on Monday the successful results of its cutting-edge drug CagriSema in combating obesity among type 2 diabetes patients. The drug achieved an average weight loss of 15.7% over 68 weeks, a significant improvement compared to the 3.1% reduction observed with a placebo.
About the Author
